DOE awards $377 million in funding for 46 energy frontier research centers
Washington, DC In a major effort to accelerate the scientific breakthroughs needed to build a new 21st-century energy economy, U.S. Energy Secretary Steven Chu announced the delivery of $377 million in funding for
46 new multi-million-dollar Energy Frontier Research Centers (EFRCs) located at uni...
Microbix Sales Grow 22% For Nine Months
Burn rate significantly reduced and Semen Sexing Technology achieves
TORONTO, Aug. 6 /PRNewswire-FirstCall/ - For
nine months ended June 30, 2009, Microbix Biosystems Inc. (TSX:MBX) announced strong sales and a significantly reduced burn rate. The third quarter had a small...
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
REDWOOD CITY, Calif.,, Aug. 6 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the publication in Cell Stem Cell of data demonstrating potent anti-cancer activity in colon ...
Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
UMEA, Sweden, August 6 /PRNewswire/ -- Omnio Healer AB, a pioneer company
developing novel therapies for
wound healing and anti-infection, today
announced that it has entered into a partnership agreement with Eden
Biodesign. Under the agreement Eden Biodesign will provide process
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced its financial results for
the second quarter ended June 30, 2009.
"We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quar...
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for
the second quarter and six months ended June 30, 2009.
"The second quarter of 2009 was a transforming quarter for
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration (FDA) has extended the Pr...
Next Safety Releases Advanced Respirator for Infectious Diseases
JEFFERSON, N.C., Aug. 5 /PRNewswire/ -- Next Safety, Inc. (NSI) announces advanced respirators that give people more confidence to go to work in a pandemic environment. Next Safety is releasing for
sale to the public respirator products the company developed for
the bird flu influenza A ...
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the Foundation for
the National Institutes of Health and sanofi-aventis announced an unprecedented donation by the global pharmaceutical leader providing approximately $1.3 million in pharmaceutical th...
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for
the treatment of antibiotic-resistant infections, today announced positive res...
Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient
ASL Pharmacy® announces the availability of Compounded Mupirocin Liquid. Mupirocin is typically only found in ointment form. ASL's compound does not contain any added ingredients, only pure mupirocin, sterile water and sterile saline. This is significant because ASL serves patients with chron...
Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for
heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for
Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
VENLO, The Netherlands, Aug. 4 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN ) today announced the Webcast of its second quarter 2009 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 11, and will include remarks by Peer M. Schatz, President ...
Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
VANCOUVER, Aug. 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced the launch of a series of new, proprietary Quill(TM) SRS product codes specifically designed for
laparoscopic, or minimally invasive, gynecology procedures, including hysterectomi...
Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009
MINNEAPOLIS, Aug. 4 /PRNewswire-FirstCall/ -- Techne Corporation's (Nasdaq: TECH ) consolidated net earnings for
the quarter ended June 30, 2009 decreased 6.9% to $25.4 million or $.68 per diluted share compared with $27.3 million or $.70 per diluted share for
the quarter ended June 30...
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN ) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for
its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs...
New Director of Lab Sales for Polymathic Analytical Labs
ORANGEBURG, S.C., Aug. 4 /PRNewswire/ -- Polymathic Analytical Labs, a Zeus company, announces that William J. Kerr will assume the role of Director of Laboratory Sales. With more than 40 years of polymer experience, Polymathic Analytical Labs' core business is the specialized and routine tes...
Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
(NYSE AMEX: SVA ), a leading provider of vaccines in China, announced today
that the clinical trial of its A/H1N1 influenza vaccine is proceeding well.
All of the volunteers received their first shot of the vaccine and, during the
Rapid heating prepares energy-saving zeolite for greater role in industrial separations
Thin-film zeolite membranes with tiny, molecule-sized pores are one step closer to replacing the energy-intensive processes now used in industrial separations, a group of academic researchers is reporting.
Writing this week in Science magazine, the group says the membranes' ability to separat...
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
BETHESDA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for
the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the Europ...
Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA ),
a leading provider of vaccines in China, announced today that the clinical
trial of its A/H1N1 influenza vaccine is proceeding well. All of the
volunteers have received their first shot of the vaccine and, during th...
NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY ) today announced that Roy J. Wu has joined the company as senior vice president for
business development. Wu brings to NovaBay more than 30 years of highly successful experience in the p...
AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for
Hoya Announces First Quarter Financial Results for FY2010
TOKYO, Japan, August 3 /PRNewswire-FirstCall/ -- HOYA Corporation today
announced financial results for
the first quarter ended June 30, 2009. Net
sales were 94.9 billion yen for
the quarter, a 27.0% decrease from 130.1
billion yen in the same period last year, and operating income was 9.2
Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software
Terrosa Technologies, a provider of Cloud and SaaS migration services and SaaS based applications, announces it has exclusive world wide sales, marketing and distribution responsibilities with Integrated Clinical Solutions for
its Inclinicalperform application. Inclinicalperform is software-as-a-...
Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
CHICAGO, July 31 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced that it received a complete response letter today from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for
Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for
the second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief execut...
China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
SHANGHAI, July 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.
(Nasdaq: CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm
specializing in the manufacture, research, development, marketing and
distribution of probiotics products, today announced it has submitted
Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
NEW BRUNSWICK, N.J., July 30 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT ) today announced that, on July 29, 2009, the Company entered into definitive purchase agreements with certain members of Senesco's Board of Directors a...
Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
SEATTLE, July 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced that it plans to issue earnings results for
its second quarter and six months ended June 30, 2009, after the close of market on Aug. 6, 2009. The company's earnings conference call w...
Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies
FT. LAUDERDALE, Fla., July 30 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for
clinical trials announced today that a growing US Clinical Research Organization (CRO) has selected OmniComm to pr...
SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
RALEIGH, N.C. , July 30 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for
the management and analysis of genetic data, today announced that it has entered into an agreement under which The Johns Hopkins Hospital will utilize SmartGene's advanced technology and integrated...
SENOMYX, INC. SECOND QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 4, 2009
SAN DIEGO, CA, July 30, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ) will release its second quarter 2009 financial results on Tuesday, August 4, 2009 before the opening of the U.S. financial markets. The Company will also host a conference call with a live Internet bro...
Sunesis Receives Approval for Listing on The NASDAQ Capital Market
SOUTH SAN FRANCISCO, Calif., July 30 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers, today announced th...
Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System
IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a market leader in laser transmyocardial revascularization (TMR), today announced that it has submitted a pre-IDE (Investigational Device Exemption) to the Food and Drug Administrat...
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced its financial results for
the three and six months ended June 30, 2009.
Adjusted diluted EPS, which excludes the impact of certain purchase acc...
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ --
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group
of companies with a focus on the development of prescription drugs that
target unmet medical needs, and MSM Protein Technologies (MSM), a human
Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up
Aztech Controls, an expert in chemical and gas handling has developed a standard gas stick that can be shipped from stock greatly minimizing lead times for
Semiconductor tool installations.
(PRWEB) July 30, 2009 -- Aztech Controls ( http://www.aztechcontrols.com ), a Ch...
NIST scientists study how to stack the deck for organic solar power
A new class of economically viable solar power cellscheap, flexible and easy to makehas come a step closer to reality as a result of recent work* at the National Institute of Standards and Technology (NIST), where scientists have deepened their understanding of the complex organic films at the hea...